Corporate Advisory and Governance, Equity Capital Markets, Mergers and Acquisitions, International, Life Sciences, Start-ups and Emerging Businesses
Naomi’s corporate experience includes advising listed companies, unlisted companies, large and small proprietary companies, individuals, and trustees.
Naomi advises clients on capital raisings (including initial public offerings and secondary capital raisings), regulated mergers and takeovers, corporate acquisitions and divestments including due diligence, share acquisitions and scrip for scrip transactions, corporate restructuring, employee incentive schemes, regulatory requirements, private equity and venture capital investments and general corporate advice (including securities trading, director’s duties and corporate governance and compliance). She also has a background in commercial litigation.
Decoding medical device classification for femtech software
Post-IPO lock-up: Protecting Australian investors at the risk of global competitiveness
Corporate Advisory Boards – try before you buy?
ASX and ASIC announce regulatory relief and clarification for listed entities
Advising on the $502 million acquisition of Viralytics Limited by Merck by scheme of arrangement.
Advising Wagners Holding Company Limited, MSL Solutions Limited, Over the Wire Holdings Limited, OtherLevels Holdings Limited and Anatara Lifesciences Limited.
Advising Viralytics Limited, Prescient Therapeutics Limited, Anatara Lifesciences Limited, Corporate Travel Management Limited, Factor Therapeutics Limited, OtherLevels Holdings Limited and Imugene Limited.
Advising on the acquisitions of Faktortel, Sanity, Spiderbox and Telarus.
Advising on the acquisition of Jeff Roorda & Associates Pty Ltd and Desktop Mapping Systems Pty Ltd.
